ALKBH5-mediated m6A modification of ID2 mRNA promotes choroidal neovascularization and subretinal fibrosis
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2025.112237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Ying Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, China; Nanjing Drum Tower Hospital, Affiliated Hospi…. Hauptthemen laut MEDLINE: Choroidal Neovascularization, AlkB Homolog 5, RNA Demethylase, RNA, Messenger, Adenosine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Choroidal neovascularization (CNV) and subretinal fibrosis are pivotal in the pathogenesis of wet age-related macular degeneration (wAMD) and contribute significantly to blindness. The role of N6-methyladenosine (m6A) modifications in the progression of wAMD remains unclear. This study identifies a significant upregulation of the RNA demethylase A-ketoglutarate dioxygenase ALKB homolog 5 (ALKBH5) in macular samples of wAMD donors. Mechanistically, ALKBH5 enhances retinal microvascular endothelial cell (RMEC) migration, angiogenesis, and endothelial-mesenchymal transition (EndMT) by upregulating DNA binding/differentiation protein 2 (ID2). Further analysis reveals that ALKBH5 interacts with the YTHDF2 binding domain of the m6A reader, which recognizes the m6A sequence on ID2 mRNA. This interaction stabilizes ID2 mRNA and modulates its m6A methylation, thereby influencing the epigenetic network in wAMD. In laser-induced CNV mouse models, ALKBH5 knockdown significantly inhibits CNV and subretinal fibrosis while protecting the retinal photoreceptor layer, thus preserving visual function. This study highlights the ALKBH5-YTHDF2-ID2 axis as a critical regulator in wAMD and suggests it as a novel therapeutic target for subretinal fibrosis in wAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, China; Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Tsingtao, China.
- Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
- National Institute of Biological Sciences, Beijing, China.
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Tsingtao, China. Electronic address: sdp5300117@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wei, Y., Hu, X., Liu, Y., Zhang, J., Zhao, L., Yang, J., Xie, Z., Shi, D., & Ma, L. (2026). ALKBH5-mediated m6A modification of ID2 mRNA promotes choroidal neovascularization and subretinal fibrosis. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112237
Vancouver
Wei Y, Hu X, Liu Y, Zhang J, Zhao L, Yang J, et al. ALKBH5-mediated m6A modification of ID2 mRNA promotes choroidal neovascularization and subretinal fibrosis. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2025.112237
BibTeX
@article{Wei2026,
author = {Wei, Ying and Hu, Xiangyue and Liu, Yujie and Zhang, Jiajia and Zhao, Lihua and Yang, Jiaqi and Xie, Zhenggao and Shi, Depeng and Ma, Li},
title = {ALKBH5-mediated m6A modification of ID2 mRNA promotes choroidal neovascularization and subretinal fibrosis},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2025.112237}
}
EUVIMED